Trial Condition(s):

Multiple Sclerosis, Chronic Progressive

China Betaferon adherence, coping and nurse support study

Bayer Identifier:

15916

ClinicalTrials.gov Identifier:

NCT01436838

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Non-adherence reduces treatment benefit and can bias the assessment of treatment efficacy thereby involving safety risks for the patient and influencing health cost-effectiveness. This observational study will concentrate upon the role of MS nurses in influencing adherence. This study will examine the influence of initial and subsequent periodic nurse interviews which aim to improve adherence to Betaferon® treatment.

Inclusion Criteria
- Relapsing-remitting multiple scelrosis (RRMS) and secondary progressive multiple sclerosis (SPMS) patients
 - Having Betaferon treatment, including patients who are
 -- First time using; or
 -- Re-staring; or
 -- Switching from other diseases modifying drugs (DMDs)
Exclusion Criteria
- Known or newly identified contraindication for administration of Betaferon according to Summary of Product Characteristic (SmPC).

Trial Summary

Enrollment Goal
110
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many locations, China

Status
Completed
 

Trial Design